Page 5 - Applied Testing News Today

(0) The therascreen KRAS RGQ PCR Kit receives U.S. regulatory approval from FDA for expanded scope to include use in guiding treatment with the newly approved therapy LUMAKRAS TM (sotorasib) from Amgen KRAS G12C mutation in NSCLC Test will be available under QIAGENs Day One Lab Readiness program QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit ( therascreen KRAS Ki...

QIAGEN N.V.: QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) QIAGEN is developing a tissue-based companion diagnosticin support of adagrasib, Miratis investigational selective KRAS G12C inhibitor Program adds to QIAGENs strong position in KRAS companion diagnostic testing in NSCLC QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) t...